BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• Business

  Marvel Biosciences Corp. Announces Change of Chief Financial Officer

  Mr. Nijjar has worked extensively with public companies across various industries, helping them navigate the regulatory and financial reporting environment.

  February 1, 2022

   · 

  1 min read
• Drug Development

  Minerva Biotechnologies Announces Opening 1st-In-Human Phase I/II Trial of a MUC1* Targeting CAR T for Metastatic Breast Cancers at City of Hope

  Minerva Biotechnologies Corporation announced today that its trial of huMNC2-CAR44 T cells (NCT04020575) has now opened at City of Hope, Duarte, California.

  February 1, 2022

   · 

  2 min read
• BioMidwest

  U.S. EPA Approves Expanded Use of LEAP® ES Bacterial Disease Management Biological Insecticide from Valent BioSciences

  Valent BioSciences has announced that the U.S. EPA (Environmental Protection Agency) has approved the expanded use of LEAP® ES Bacterial Disease Management Biological Insecticide.

  February 1, 2022

   · 

  1 min read
• BioMidwest

  CND Life Sciences Closes Series Seed 2 Round, Reaches $8 Million In Total Capital Raised

  CND Life Sciences, Inc., an innovative medical diagnostics company pioneering the detection, visualization, and quantification of protein deposition in cutaneous nerve fibers, announced the closing of a $5.0 million Series Seed 2 financing round.

  February 1, 2022

   · 

  4 min read
• Business

  Pfizer Announces New Chief Development Officer

  Pfizer Inc. (NYSE: PFE) today announced that William Pao, M.D., Ph.D., will join the Company as Executive Vice President and Chief Development Officer effective March 21, 2022.

  February 1, 2022

   · 

  5 min read
• BioMidwest

  Lilly to Participate in Guggenheim Oncology Conference - Feb 01, 2022

  Eli Lilly and Company will participate in the Guggenheim Oncology Conference on Wednesday, Feb. 9, 2022.

  February 1, 2022

   · 

  1 min read
• Business

  Kronos Bio Announces Appointment of Elizabeth Olek as Senior Vice President of Clinical Development

  Kronos Bio, Inc. today announced the appointment of Dr. Elizabeth Olek, DO, MPH, as senior vice president, Clinical Development.

  February 1, 2022

   · 

  3 min read
• Transfer of OSE Immunotherapeutics’ Shares from Compartment C to Compartment B of Euronext Paris from January 31, 2022

  OSE Immunotherapeutics SA announced that its shares have been transferred from compartment C to compartment B of Euronext Paris.

  February 1, 2022

   · 

  5 min read
• Business

  Novozymes delivers strong 2021 full-year results and expects continued, solid progress in 2022

  In the 2021 financial year, Novozymes delivers 6% organic sales growth – 7% organic sales growth in the fourth quarter alone – an EBIT-margin of 26.8%, and ROIC including goodwill of 19.3%.

  February 1, 2022

   · 

  4 min read
• Business

  OKYO Pharma Limited (“OKYO” or the “Company”) - Grant of options – Director and PDMR dealings

  OKYO Pharma Limited announces that the board of directors of the Company, acting on a recommendation of the Remuneration Committee with Mr Brancaccio and Mr Denoyer absenting themselves on grounds of interest, has awarded the following options on 31 January 2022.

  February 1, 2022

   · 

  4 min read